News Search Results
Apr 08, 2025, 08:00 ET Freenome Names Aaron Elliott, Ph.D., as Chief Executive Officer to Lead the Company's Next Chapter of Commercial Growth and Product Innovation
BRISBANE, Calif., April 8, 2025 /PRNewswire/ -- Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the appointment of Aaron Elliott, Ph.D., as
More news about: Freenome Holdings, Inc.
Apr 08, 2025, 05:45 ET Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
April 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Apr 08, 2025, 05:45 ET Shareholders that lost money on ICON Public Limited Company(ICLR) should contact Levi & Korsinsky about pending Class Action - ICLR
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Levi & Korsinsky, LLP
Apr 08, 2025, 01:00 ET Synthego and Vita Therapeutics Announce Strategic Licensing Agreement for hfCas12Max CRISPR Nuclease
high-fidelity nuclease portfolio, delivering new opportunities for therapeutic advancement. About SynthegoSynthego is a leader in biotechnology, dedicated to delivering best-in-class CRISPR solutions with a mission to accelerate research and development in the pursuit of improved human health.
More news about: Synthego
Apr 08, 2025, 00:01 ET National Security Commission on Emerging Biotechnology Urges Swift Action to Protect U.S. National Security
finds that emerging biotechnology is rapidly advancing, and the impact of biotechnology innovation already extends far beyond health, touching industries from agriculture and infrastructure, to manufacturing and defense. The intersection of artificial intelligence (AI) and biotechnology is accelerating this
More news about: National Security Commission on Emerging Biotechnology
Apr 07, 2025, 17:14 ET NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates
April 7, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a clinical-stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today reports its financial results for the year ended December
More news about: NeuroSense
Apr 07, 2025, 16:05 ET INVESTOR DEADLINE THIS WEEK: ICON PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
insufficient to shield ICON from the adverse effects of a significant market downturn; (iii) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Robbins Geller Rudman & Dowd LLP
Apr 07, 2025, 16:01 ET Innocan Pharma Broadens Intellectual Property Coverage for its Liposomal CBD Injection Across Asia and Announces Private Placement of Units
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that a divisional application for its Chinese (CN) liposome-based CBD technology patent was filed.
More news about: Innocan Pharma Corporation
Apr 07, 2025, 16:01 ET Innocan Pharma Broadens Intellectual Property Coverage for its Liposomal CBD Injection Across Asia and Announces Private Placement of Units
2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that a divisional application for its Chinese (CN) liposome-based CBD technology patent was filed.
More news about: Innocan Pharma Corporation
Apr 07, 2025, 14:14 ET NC Community Colleges Shine in Statewide Celebration of Excellence
amazing faculty and staff." The Excellence in Teaching Award to Dr. Lisa Smelser, Biotechnology Chair at Central Carolina Community College, presented by the
More news about: North Carolina Community College System
Apr 07, 2025, 10:30 ET US Single-Cell Analysis Market worth US$2,695.3 million by 2029 with 14.3% CAGR | MarketsandMarkets™
segment growth. By Based on end user, the US single-cell analysis market is segmented into academic & research laboratories, biotechnology & pharmaceutical companies, hospitals & diagnostic laboratories, and cell banks & IVF centers. The academic & research laboratories
More news about: MarketsandMarkets
Apr 07, 2025, 10:15 ET United States (USA) Testing, Inspection and Certification (TIC) Market worth $55.66 billion by 2030 - Exclusive Report by MarketsandMarkets™
pressure and patient safety and product effectiveness concerns. The development of medical technologies such as medical devices, pharmaceuticals, biotechnology products, and diagnostic tools has increased the need for more stringent testing and certification processes. Furthermore, the increased incidence
More news about: MarketsandMarkets
Apr 07, 2025, 09:29 ET European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Apr 07, 2025, 09:28 ET SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:
More news about: The Schall Law Firm
Apr 07, 2025, 09:00 ET Pivot Bio Announces Appointment of Travis Frey as Chief Technology Officer
in plant breeding and plant genetics from the University of Wisconsin-Madison. He holds a Ph.D. in plant biology and biotechnology from the University of Delaware and Dupont/Pioneer. In addition, in 2018, Frey completed an MBA at the University
More news about: Pivot Bio, Inc
Apr 07, 2025, 08:30 ET Mission BioCapital Announces 2024 Platinum Ticket Investments and Opening of $4 Million 2025 Platinum Program Contest
will be required for application. "Developing a biotechnology discovery into a commercial product is a complex process. We are excited to join the Mission BioCapital Platinum Program sponsorship consortium to help worthwhile biotechnology start-ups access foundational technologies that enable
More news about: Mission BioCapital
Apr 07, 2025, 08:30 ET Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences
Incorporated at (877) 750-8310 (toll-free) or (212) 750-5833. About Aerovate Therapeutics, Inc. Aerovate Therapeutics is a biotechnology company that was focused on improving the lives of patients with rare cardiopulmonary disease. For more information, please visit www.aerovatetx.com.
More news about: Aerovate Therapeutics
Apr 07, 2025, 08:24 ET TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management
cancer." Prior to joining TuHURA, Dr. Le Bourdonnec served as the Chief Scientific Officer and Scientific Advisor for HDAX Therapeutics, a biotechnology company pioneering a novel approach to targeting HDAC6 for the discovery and development of breakthrough therapeutics for high unmet medical needs.
More news about: TuHURA Biosciences, Inc.
Apr 07, 2025, 05:45 ET Shareholders of Sana Biotechnology, Inc. Should Contact The Gross Law Firm Before May 20, 2025 to Discuss Your Rights - SANA
April 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
More news about: The Gross Law Firm
Apr 07, 2025, 05:45 ET Class Action Filed Against ICON Public Limited Company (ICLR) Seeking Recovery for Investors - Contact The Gross Law Firm
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: The Gross Law Firm
Apr 05, 2025, 18:30 ET Breakthrough Prize Foundation Announces Student Winner of 10th Annual Breakthrough Junior Challenge Science Video Competition
idea in a really smart, original and funny way." Jasmine's winning entry explains mechanogenetic cellular engineering, an innovative biotechnology, exploring how it works and its potential as a medical tool in the future. The short film can be seen
More news about: The Breakthrough Prize
Apr 04, 2025, 16:05 ET Spyre Therapeutics Announces Grants of Inducement Awards
April 4, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience
More news about: Spyre Therapeutics, Inc.
Apr 04, 2025, 16:05 ET China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split
across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about
More news about: China Pharma Holdings, Inc.
Apr 04, 2025, 12:00 ET ICON plc (ICLR) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
offerings were insufficient to shield the Company from the adverse effects of a significant market downturn; (3) that the RFPs ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Apr 04, 2025, 09:30 ET SkylineDx Presents Landmark Study on Merlin CP-GEP beyond SLNB prediction: Transforming Melanoma Risk Assessment
diagnostic service providers globally to bring this test to market and increase patient access. About SkylineDx SkylineDx is a biotechnology company focused on research & development of molecular diagnostics in oncology inflammatory, and infectious diseases. SkylineDx uses its expertise
More news about: SkylineDx